AMGN vs LLY: Amgen vs Eli Lilly Stock Comparison: AI Score, Valuation, Performance and Upside
Eli Lilly is the highest-conviction GLP-1 obesity drug play in the market, with Mounjaro and Zepbound generating extraordinary revenue growth; Amgen is a larger, more diversified biotech at a much lower valuation with MariTide as a potential obesity market entry option. LLY has current execution momentum; AMGN offers a cheaper entry point with obesity optionality if MariTide data is positive.
Use this AMGN vs LLY comparison to choose between the dominant obesity drug franchise and a diversified biotech with obesity optionality. Lilly's valuation reflects its dominant GLP-1 position; Amgen's valuation reflects its diversified legacy portfolio with MariTide as a speculative upside call option on the same obesity market.
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- Want exposure to a diversified large-cap biotech at a much lower valuation than LLY
- Value Amgen's biosimilar manufacturing leadership as a growing and durable revenue stream
- See MariTide as a speculative call option on obesity market entry at a lower cost of entry than LLY
- Prefer a higher dividend yield from a profitable, established biotech franchise
- Want the dominant GLP-1 obesity franchise with the fastest-growing pharmaceutical products in history
- Believe the global obesity epidemic represents a multi-decade pharmaceutical growth market worth owning at a premium
- Value Mounjaro/Zepbound's manufacturing ramp as the primary near-term catalyst for revenue acceleration
- Are comfortable with a premium valuation in exchange for the highest-conviction obesity drug exposure available
| Metric | AMGN | LLY |
|---|---|---|
| AI scorei | N/A | N/A |
| AI ranki | N/A | N/A |
| Latest closei | N/A | N/A |
| Metric | AMGN | LLY |
|---|---|---|
| Market capi | N/A | N/A |
| Trailing P/Ei | N/A | N/A |
| Forward P/Ei | N/A | N/A |
| Price/Salesi | N/A | N/A |
| EV/Revenuei | N/A | N/A |
| Analyst targeti | N/A | N/A |
| Target upsidei | N/A | N/A |
| Metric | AMGN | LLY |
|---|---|---|
| Revenue growthi | N/A | N/A |
| Earnings growthi | N/A | N/A |
| EPS growthi | N/A | N/A |
| FCF margini | N/A | N/A |
| Operating margini | N/A | N/A |
| Profit margini | N/A | N/A |
| ROIC proxyi | N/A | N/A |
| Return on equityi | N/A | N/A |
| Dividend yieldi | N/A | N/A |
| Payout ratioi | N/A | N/A |
| Dividend growth streaki | N/A | N/A |
| Betai | N/A | N/A |
| Debt/equityi | N/A | N/A |
| Current ratioi | N/A | N/A |
| Quick ratioi | N/A | N/A |
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | AMGN | LLY |
|---|---|---|---|
| 1Y | Growthi | N/A | N/A |
| CAGRi | N/A | N/A | |
| Volatilityi | N/A | N/A | |
| Sharpe ratioi | N/A | N/A | |
| Sortino ratioi | N/A | N/A | |
| Max drawdowni | N/A | N/A | |
| Current drawdowni | N/A | N/A | |
| Avg drawdowni | N/A | N/A | |
| Ulcer Indexi | N/A | N/A | |
| Max daily dropi | N/A | N/A | |
| Max wkly dropi | N/A | N/A | |
| 5Y | Growthi | N/A | N/A |
| CAGRi | N/A | N/A | |
| Volatilityi | N/A | N/A | |
| Sharpe ratioi | N/A | N/A | |
| Sortino ratioi | N/A | N/A | |
| Max drawdowni | N/A | N/A | |
| Current drawdowni | N/A | N/A | |
| Avg drawdowni | N/A | N/A | |
| Ulcer Indexi | N/A | N/A | |
| Max daily dropi | N/A | N/A | |
| Max wkly dropi | N/A | N/A | |
| 10Y | Growthi | N/A | N/A |
| CAGRi | N/A | N/A | |
| Volatilityi | N/A | N/A | |
| Sharpe ratioi | N/A | N/A | |
| Sortino ratioi | N/A | N/A | |
| Max drawdowni | N/A | N/A | |
| Current drawdowni | N/A | N/A | |
| Avg drawdowni | N/A | N/A | |
| Ulcer Indexi | N/A | N/A | |
| Max daily dropi | N/A | N/A | |
| Max wkly dropi | N/A | N/A |
| Category | AMGN | LLY |
|---|---|---|
| Company | Amgen Inc. | Eli Lilly and Company |
| Sector | Biotechnology | Pharmaceuticals |
| Industry | N/A | N/A |
| Core business | Large-cap biotech with a diversified portfolio including Enbrel, Otezla, Prolia, EVENITY, Repatha, and Lumakras. Acquired Horizon Therapeutics in 2023 (rare disease). Developing MariTide (GLP-1/GIP obesity treatment) as a potential entry into the obesity market. | One of the world's most valuable pharmaceutical companies. GLP-1 drugs Mounjaro (tirzepatide, diabetes) and Zepbound (tirzepatide, obesity) are the fastest-growing pharmaceutical products ever launched. Also markets Verzenio (breast cancer), Jardiance (diabetes), and Taltz (immunology). Developing next-generation obesity drugs (oral GLP-1, retatrutide). |
| Investor focus | MariTide obesity drug clinical data and commercial potential, Horizon rare disease portfolio integration, biosimilar revenue ramp, and dividend growth. | Mounjaro and Zepbound demand relative to supply capacity, obesity pipeline (orforglipron oral GLP-1, retatrutide), international GLP-1 expansion, and manufacturing ramp to meet demand. |
- Large, diversified biologics portfolio with multiple products in stable therapeutic categories
- MariTide obesity drug candidate — if Phase 3 data confirms Phase 2 results, represents a massive new market opportunity
- Amgen is the world's leading biosimilar manufacturer — a growing revenue stream from generic versions of biologics
- Mounjaro/Zepbound are among the most commercially successful drug launches in pharmaceutical history
- Obesity drug pipeline (oral GLP-1, retatrutide) extends the franchise beyond tirzepatide
- Premium valuation is partially justified by the sheer scale of the global obesity epidemic as the addressable market
- Core portfolio faces biosimilar competition on key drugs like Enbrel and Prolia over time
- MariTide is still in clinical development — obesity market entry is not guaranteed and execution risk is high
- Horizon acquisition added significant debt, and the rare disease portfolio is smaller-scale than Amgen's traditional blockbusters
- Manufacturing capacity has been supply-constrained — failure to expand production limits revenue realisation
- Novo Nordisk (semaglutide) is the primary competitor — losing market share to Ozempic/Wegovy would be significant
- Premium valuation prices in a significant portion of the long-term obesity opportunity — disappointment is costly
Compare more than two at a time
This page is a fixed writeup on AMGN and LLY. Our comparison engine is the interactive version: load up to five tickers, switch timeframes, and get the correlation, drawdown, and overlap analysis that a static page can't show.
Add three more names beside AMGN and LLY, mixing stocks and ETFs in the same table — useful when the real question is which of a whole peer group to own.
AI score, forward P/E, analyst target upside, operating margin, and revenue growth are scored head-to-head, with a running tally of which ticker leads on how many metrics.
Volatility, Sharpe and Sortino ratios, maximum, current, and average drawdown, Ulcer Index, and worst single-day and single-week drops across every timeframe.
Pairwise daily-return correlation for every combination, so you can see whether two holdings actually diversify each other or just move together.
A scatter plot of forward P/E against return on equity, plus drawdown and 30-day rolling volatility charts, to separate what is cheap from what is merely beaten down.
For ETFs, a top-holdings comparison that exposes hidden overlap between funds. Every comparison exports to CSV for your own spreadsheet work.
Two comparisons a week are free without an account. A 14-day trial removes the limit and adds AI price forecasts, stock rankings, saved watchlists, and the intrinsic value calculator — no credit card required.
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.